Could a diabetes drug stop heart failure before it starts?
NCT ID NCT06055452
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a daily pill called engagliflozin (a type of SGLT2 inhibitor) can improve heart function in people who have high blood pressure and early signs of heart failure but do not have diabetes. About 120 adults will receive either the drug or a placebo for 6 months. The main goal is to see if the drug reduces the size of the heart's left upper chamber, which is a marker of heart strain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen
RECRUITINGShenzhen, Guangdong, 518038, China
-
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100037, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a few short nights of sleep tip the scales toward high blood pressure?
- Chatbot could put blood pressure control in Patients' hands
- Can a 5-Step chat help tame high blood pressure?
- Can artery scans reveal hidden damage from high blood pressure?
- CRISPR injection could rewrite the future of blood pressure control
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?